Helix Biopharma Corp. (HBPCF), a Toronto-based biopharmaceutical company, recently announced its financial results for the fiscal fourth quarter, revealing a net loss of $3.9 million. This loss translates to 8 cents per share, highlighting challenges the company faced during the quarter. The reported figures underscore ongoing financial pressures, which are not uncommon in the biotechnology...
Related Posts
Subscribe to Updates
Get the latest news and updates directly to your inbox.
© 2025 Arcalis News. All Rights Reserved.